I. Ertenli Et Al. , "Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.," Rheumatology international , vol.32, no.2, pp.323-30, 2012
Ertenli, I. Et Al. 2012. Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.. Rheumatology international , vol.32, no.2 , 323-30.
Ertenli, I., Ozer, S., Kiraz, S., Apras, S. B., Akdogan, A., Karadag, O., ... Calguneri, M.(2012). Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.. Rheumatology international , vol.32, no.2, 323-30.
Ertenli, I. Et Al. "Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.," Rheumatology international , vol.32, no.2, 323-30, 2012
Ertenli, I. Et Al. "Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.." Rheumatology international , vol.32, no.2, pp.323-30, 2012
Ertenli, I. Et Al. (2012) . "Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.." Rheumatology international , vol.32, no.2, pp.323-30.
@article{article, author={I. Ertenli Et Al. }, title={Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.}, journal={Rheumatology international}, year=2012, pages={323-30} }